These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 37107147)

  • 1. In Vitro Activity of Cefiderocol on Multiresistant Bacterial Strains and Genomic Analysis of Two Cefiderocol Resistant Strains.
    Padovani M; Bertelli A; Corbellini S; Piccinelli G; Gurrieri F; De Francesco MA
    Antibiotics (Basel); 2023 Apr; 12(4):. PubMed ID: 37107147
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Activity of cefiderocol against high-risk clones of multidrug-resistant Enterobacterales, Acinetobacter baumannii, Pseudomonas aeruginosa and Stenotrophomonas maltophilia.
    Delgado-Valverde M; Conejo MDC; Serrano L; Fernández-Cuenca F; Pascual Á
    J Antimicrob Chemother; 2020 Jul; 75(7):1840-1849. PubMed ID: 32277821
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Occurrence of High Levels of Cefiderocol Resistance in Carbapenem-Resistant Escherichia coli before Its Approval in China: a Report from China CRE-Network.
    Wang Q; Jin L; Sun S; Yin Y; Wang R; Chen F; Wang X; Zhang Y; Hou J; Zhang Y; Zhang Z; Luo L; Guo Z; Li Z; Lin X; Bi L; Wang H
    Microbiol Spectr; 2022 Jun; 10(3):e0267021. PubMed ID: 35481835
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Activity of Cefiderocol Against
    Iregui A; Khan Z; Landman D; Quale J
    Microb Drug Resist; 2020 Jul; 26(7):722-726. PubMed ID: 32031915
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cefiderocol: A Siderophore Cephalosporin with Activity Against Carbapenem-Resistant and Multidrug-Resistant Gram-Negative Bacilli.
    Zhanel GG; Golden AR; Zelenitsky S; Wiebe K; Lawrence CK; Adam HJ; Idowu T; Domalaon R; Schweizer F; Zhanel MA; Lagacé-Wiens PRS; Walkty AJ; Noreddin A; Lynch Iii JP; Karlowsky JA
    Drugs; 2019 Feb; 79(3):271-289. PubMed ID: 30712199
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro activity of the novel siderophore cephalosporin, cefiderocol, in Gram-negative pathogens in Europe by site of infection.
    Candel FJ; Santerre Henriksen A; Longshaw C; Yamano Y; Oliver A
    Clin Microbiol Infect; 2022 Mar; 28(3):447.e1-447.e6. PubMed ID: 34298176
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro activity of cefiderocol and comparators against Gram-negative bacterial isolates from a series of surveillance studies in England: 2014-2018.
    Gant V; Hussain A; Bain M; Longshaw C; Henriksen AS
    J Glob Antimicrob Resist; 2021 Dec; 27():1-11. PubMed ID: 34329792
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In Vitro Antimicrobial Activity of the Siderophore Cephalosporin Cefiderocol against
    Carcione D; Siracusa C; Sulejmani A; Migliavacca R; Mercato A; Piazza A; Principe L; Clementi N; Mancini N; Leoni V; Intra J
    Antibiotics (Basel); 2021 Oct; 10(11):. PubMed ID: 34827247
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro activity of cefiderocol and other newly approved antimicrobials against multi-drug resistant Gram-negative pathogens recovered in intensive care units in Spain and Portugal.
    Gijón D; García-Castillo J; Fernández-López MC; Bou G; Siller M; Calvo-Montes J; Pitart C; Vila J; Torno N; Gimeno C; Cruz H; Ramos H; Mulet X; Oliver A; Ruiz-Garbajosa P; Canton R
    Rev Esp Quimioter; 2024 Feb; 37(1):69-77. PubMed ID: 37882320
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vitro activity of cefiderocol against clinically important carbapenem non-susceptible Gram-negative bacteria from Saudi Arabia.
    Alzayer M; Alghoribi MF; Alalwan B; Alreheli A; Aljohani S; Bosaeed M; Doumith M
    J Glob Antimicrob Resist; 2023 Mar; 32():176-180. PubMed ID: 36481491
    [TBL] [Abstract][Full Text] [Related]  

  • 11.
    Mushtaq S; Sadouki Z; Vickers A; Livermore DM; Woodford N
    Antimicrob Agents Chemother; 2020 Nov; 64(12):. PubMed ID: 32958717
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro activity of cefiderocol, a siderophore cephalosporin, against a recent collection of clinically relevant carbapenem-non-susceptible Gram-negative bacilli, including serine carbapenemase- and metallo-β-lactamase-producing isolates (SIDERO-WT-2014 Study).
    Kazmierczak KM; Tsuji M; Wise MG; Hackel M; Yamano Y; Echols R; Sahm DF
    Int J Antimicrob Agents; 2019 Feb; 53(2):177-184. PubMed ID: 30395986
    [TBL] [Abstract][Full Text] [Related]  

  • 13.
    Hackel MA; Tsuji M; Yamano Y; Echols R; Karlowsky JA; Sahm DF
    Antimicrob Agents Chemother; 2017 Sep; 61(9):. PubMed ID: 28630181
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vitro antibacterial activity of cefiderocol against recent multidrug-resistant carbapenem-nonsusceptible Enterobacterales isolates.
    Zhang Q; Neidig N; Chu TY; Divoky C; Carpenter J; Lee-Hsiao C; Threatt H; Sultana R; Bush K
    Diagn Microbiol Infect Dis; 2022 May; 103(1):115651. PubMed ID: 35228130
    [TBL] [Abstract][Full Text] [Related]  

  • 15.
    Longshaw C; Manissero D; Tsuji M; Echols R; Yamano Y
    JAC Antimicrob Resist; 2020 Sep; 2(3):dlaa060. PubMed ID: 34223017
    [TBL] [Abstract][Full Text] [Related]  

  • 16.
    Naas T; Lina G; Santerre Henriksen A; Longshaw C; Jehl F
    JAC Antimicrob Resist; 2021 Jun; 3(2):dlab081. PubMed ID: 34223140
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Susceptibility of cefiderocol and other antibiotics against carbapenem-resistant, Gram-negative bacteria.
    Wang Y; Li Y; Zhao J; Guan J; Ni W; Gao Z
    Ann Transl Med; 2022 Mar; 10(5):261. PubMed ID: 35402576
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Performance evaluation of Bruker UMIC
    Bianco G; Boattini M; Comini S; Gaibani P; Cavallo R; Costa C
    Eur J Clin Microbiol Infect Dis; 2024 Mar; 43(3):559-566. PubMed ID: 38240988
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Activity of the novel siderophore cephalosporin cefiderocol against multidrug-resistant Gram-negative pathogens.
    Dobias J; Dénervaud-Tendon V; Poirel L; Nordmann P
    Eur J Clin Microbiol Infect Dis; 2017 Dec; 36(12):2319-2327. PubMed ID: 28748397
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evolution of cefiderocol resistance in
    Werth BJ; Ashford NK; Penewit K; Waalkes A; Holmes EA; Bryan A; Salipante SJ
    JAC Antimicrob Resist; 2022 Mar; 4(1):dlac011. PubMed ID: 35156034
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.